Survodutide: Evidence, Safety, Dosing Studied, and Access Questions

Survodutide, also known as BI 456906, is a dual glucagon and GLP-1 receptor agonist studied in human trials for obesity, type 2 diabetes markers, MASH, MASLD, fibrosis, and cirrhosis-related liver disease. Chia has not verified an FDA approval for survodutide for these uses as of 2026-09-11. Published randomized trials exist, but trial protocols should not be used as personal dosing instructions.

What it is

Survodutide is the generic INN name for BI 456906, a drug studied as a dual glucagon receptor and GLP-1 receptor agonist. It has no brand name supplied in the evidence records provided for this article.

In plain English, survodutide is part of the incretin-therapy family, but it is not a single-pathway GLP-1 medication. Human studies describe it as acting at both the glucagon receptor and the GLP-1 receptor, and researchers have studied it in obesity, overweight, type 2 diabetes, MASH, MASLD, liver fibrosis, and cirrhosis-related liver disease; Chia has not verified an FDA approval for survodutide for these uses as of 2026-09-11 2 3 5 7.

Survodutide at a glance: names, class, and research focus

Mechanism of action

Survodutide is described in human research as a dual agonist at glucagon and GLP-1 receptors. That means it is designed to activate two hormone pathways involved in appetite, weight regulation, glucose handling, and energy balance, but patient-level effects depend on the population studied and the trial design 2 10 11.

Dual glucagon and GLP-1 receptor agonism

GLP-1 receptor agonism is the part many people recognize from medications such as semaglutide, which FDA labeling describes as a GLP-1 receptor agonist 14. In survodutide studies, the added glucagon receptor activity is the key difference, and trials have evaluated body weight, HbA1c, beta-cell function biomarkers, insulin sensitivity markers, and liver-disease endpoints 3 12.

How this differs from single GLP-1 receptor agonists

Single GLP-1 receptor agonists focus on the GLP-1 receptor pathway. Survodutide is studied as a dual glucagon/GLP-1 receptor agonist, while tirzepatide is described in FDA labeling as a dual GIP/GLP-1 receptor agonist; these are different receptor targets, so trial results should not be treated as interchangeable 2 3 13.

If you are comparing incretin options, it may help to read about older GLP-1 medicines such as exenatide, dulaglutide, and liraglutide. Those pages explain how GLP-1-only drugs differ from newer multi-receptor drugs.

Evidence

Evidence grade: A. Survodutide has two or more human randomised controlled trials indexed in PubMed, including studies in obesity, type 2 diabetes, MASH with fibrosis, MASLD, and metabolic biomarkers 1 2 3 4 7.

What conditions has survodutide been studied for?

For obesity and overweight, survodutide has been studied in randomized, double-blind, placebo-controlled trials, including dose-finding phase 2 research and later phase 3 trial publications 2 4 6. A subgroup analysis also looked at sex and baseline BMI in people with BMI ≥27 kg/m² from the phase 2 trial 9.

For type 2 diabetes and metabolic markers, a randomized clinical trial studied dose-response effects on HbA1c and body weight versus placebo and open-label semaglutide in people with type 2 diabetes 3. Another randomized study reported biomarker outcomes related to beta-cell function and insulin sensitivity in people with type 2 diabetes or people living with overweight or obesity 12.

For liver disease, survodutide has been studied in a phase 2 randomized trial in MASH and fibrosis, in a phase 3 randomized trial in adults with obesity and MASLD, and in a clinical trial evaluating efficacy, tolerability, and pharmacokinetics in cirrhosis 1 5 7.

What the human evidence shows so far

The obesity evidence includes a randomized, double-blind, placebo-controlled dose-finding phase 2 trial and a later once-weekly study in adults with obesity 2 4. These studies are useful because they are human randomized trials, but individual results vary and trial populations may not match a given patient.

The diabetes evidence includes a randomized trial in people with type 2 diabetes that evaluated HbA1c and body weight, and a separate biomarker study focused on beta-cell function and insulin sensitivity 3 12. These are metabolic endpoints, not a substitute for a clinician deciding which medication fits a patient’s overall risk profile.

The liver-disease evidence is notable because trials have studied MASH, MASLD, fibrosis, and cirrhosis-related populations 1 5 7. At the same time, liver-disease populations can have different safety needs, drug-handling issues, and monitoring needs than general obesity populations.

Evidence limits patients should understand

An A grade does not mean “works for everyone” or “safe for everyone.” It only means the quantity and design of evidence include at least two human randomized controlled trials; it does not settle long-term safety, access, individual dosing, or whether one patient should use it.

Another limit is comparison. Survodutide, semaglutide, tirzepatide, and other incretin therapies are often discussed together, but trials differ in study design, population, endpoints, and background care, so cross-trial comparisons can mislead patients 2 3 4.

What studies exist

This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-11.

Reported dosing ranges

Trial dosing is not personal dosing advice. The retrieved evidence includes phase 1 studies, dose-response research, dose-finding obesity research, and a once-weekly obesity trial, but the article source records provided here do not supply patient-ready dosing instructions 2 3 4 10 11.

Trial dosing is not personal dosing advice

Clinical trials use strict inclusion rules, monitoring plans, stop rules, and dose schedules chosen for research. A trial schedule should never be copied into personal use, especially for a medication being studied in people with obesity, diabetes, or liver disease 1 3 5.

Why online dosing calculators are not reliable for research compounds

Online dosing calculators often ignore trial entry criteria, medical history, kidney or liver disease, other medications, and adverse-event monitoring. For a compound studied in metabolic and liver-disease populations, that missing context can be clinically important 1 5 7.

Legal status

Our regulatory log holds no confirmed federal action for Survodutide. That means we have not found one with a primary source — not that none exists.

This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-11. See the full legal-status tracker for every compound we follow.

Safety

Safety evidence for survodutide includes phase 1 studies evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics, plus later trials in obesity, type 2 diabetes, and liver-disease populations 3 5 10 11. That is meaningful human evidence, but it does not remove the need for clinician review.

Tolerability findings from obesity and metabolic trials

The retrieved records identify tolerability and safety as studied outcomes in phase 1 and cirrhosis research, and body weight, HbA1c, beta-cell biomarkers, and insulin sensitivity markers as studied metabolic outcomes 3 5 10 12. The records provided here do not give a complete adverse-event table, so this page should not pretend the side-effect profile is fully settled.

Safety questions in liver disease populations

Liver-disease research is a separate safety question because cirrhosis, fibrosis, MASH, and MASLD can affect medication handling, nutrition, dehydration risk, and monitoring needs. Survodutide has been studied in MASH with fibrosis, MASLD, and cirrhosis-related populations, but those results should be interpreted by clinicians familiar with liver disease 1 5 7.

Why long-term safety is still being studied

Even when several randomized trials exist, longer and broader follow-up can reveal questions not seen in early or selected trial groups. Phase 3 publications and biomarker studies expand the evidence base, but they still do not answer every long-term safety question for every patient group 4 6 7 8 12.

Risks of unregulated supply

A “research use only” product from an unregulated vendor is not medical care. Without a licensed clinician and a state-licensed pharmacy process, patients may face identity, strength, impurity, sterility, storage, and follow-up risks that clinical trials are designed to control.

Interactions

Interaction data are limited in the retrieved PubMed records. The evidence provided here includes studies of pharmacokinetics, pharmacodynamics, HbA1c, body weight, insulin sensitivity markers, and liver-disease populations, but it does not provide a full drug-interaction map for patients 3 5 10 11 12.

Diabetes medications and glucose-lowering risk discussions

People with type 2 diabetes need a clinician to review glucose-lowering medications, HbA1c, kidney function, nutrition, and hypoglycemia risk when discussing incretin therapies. Survodutide has been studied in people with type 2 diabetes and in metabolic biomarker research, but that does not replace medication-by-medication review 3 8 12.

Digestive symptoms, dehydration risk, and medication absorption questions

For incretin-based therapies, clinicians commonly ask about digestive symptoms, hydration, nutrition, and oral medications that could be affected if nausea, vomiting, or reduced intake occurs. The retrieved survodutide records include tolerability and pharmacokinetic research, but they do not provide a complete patient-specific absorption or interaction guide 5 10 11.

Liver disease and kidney disease questions

Patients with liver disease need extra caution because trial populations, fibrosis stage, cirrhosis status, labs, and current medicines matter. Survodutide has been studied in MASH with fibrosis, MASLD, and cirrhosis-related research, so a liver-focused clinician review is important when discussing those data 1 5 7.

How to obtain it legally

Survodutide is not listed in Chia’s live treatment catalog, so we do not present it as a Chia treatment option. If you are asking about weight-loss medication, our providers can instead review whether a listed option such as tirzepatide tablets or injections or semaglutide injection may fit your goals and medical history.

At Chia, care starts with a 100% online health questionnaire. A licensed US provider reviews your history, medications, goals, and safety factors, then prescribes only when clinically appropriate; a prescription is never guaranteed.

When Chia prescribes a treatment we offer, medications are compounded in the US by state-licensed 503A compounding pharmacies and shipped to the patient’s door. Dosing is provider-guided and adjusted over time where appropriate, including microdosing plans for tirzepatide and semaglutide. Compounded medications are not FDA-approved.

How does survodutide compare with tirzepatide or Mounjaro?

Survodutide and tirzepatide are both multi-receptor incretin therapies, but they target different receptor pairs. Survodutide is studied as a glucagon/GLP-1 receptor agonist, while tirzepatide is described in FDA labeling as a GIP/GLP-1 receptor agonist; Mounjaro is a brand-name tirzepatide product, and compounded tirzepatide is a separate compounded formulation 2 3 13.

Patients should be careful with head-to-head claims unless the same trial directly compares the options in the same population. The retrieved survodutide records include obesity, type 2 diabetes, metabolic biomarker, and liver-disease studies, but they do not make every real-world treatment choice obvious for an individual person 1 3 4 7 12.

What to bring to a clinical visit

• Your current weight, height, waist size if available, and weight-history timeline.
• Recent labs, including HbA1c, fasting glucose, lipids, kidney markers, and liver markers if you have them.
• A list of current medications and supplements, especially diabetes medications.
• Your history of gallbladder disease, pancreatitis, liver disease, kidney disease, severe digestive disease, or eating disorder symptoms.
• Your goals: weight, energy, metabolic health, liver-health questions, or medication tolerability.
• Questions about Chia’s online visit can start with the eligibility quiz, but a prescription is never guaranteed.

Keep reading

Weight Management

Mazdutide: Evidence, Safety, Dosing Studied, and Access Questions

Weight Management

Cagrilintide: Evidence, Safety, Dosing Research, and Access Questions

Weight Management

Exenatide: Evidence, Safety, Dosing and Access Questions